• Exploring how payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOPI- Inhibitors

• Presenting novel linker technologies for stable conjugation and traceless release of hydroxy-containing drugs to expand the payload space in ADCs

• Discussing how resulting ADCs are homogenous at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy